Literature DB >> 17349723

Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection.

Yu Cong1, Madhulika Jupelli, M Neal Guentzel, Guangming Zhong, Ashlesh K Murthy, Bernard P Arulanandam.   

Abstract

We have reported recently that intranasal (i.n.) vaccination with chlamydial protease-like activity factor (CPAF) and interleukin-12 (IL-12) enhances protective immunity against genital chlamydial challenge. In this study, we show that i.n. or intraperitoneal (i.p.) vaccination with CPAF plus CpG deoxynucleotides (CpG), an alternative T helper 1 (Th1) adjuvant, induced robust CPAF-specific IFN-gamma responses and elevated levels of serum antibody and vaginal IgA production. CPAF+CpG vaccinated animals displayed accelerated genital chlamydial clearance, and minimal hydrosalpinx and inflammatory cellular infiltration compared to mock-immunized (PBS) challenged animals. Together, CpG dexoynucleotides are an efficacious alternative Th1 adjuvant with CPAF to induce protective anti-chlamydial immunity.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17349723      PMCID： PMC2757645          DOI： 10.1016/j.vaccine.2007.02.010

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  42 in total

Review 1.  CpG motifs in bacterial DNA and their immune effects.

Authors:  Arthur M Krieg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

2.  The secreted protease factor CPAF is responsible for degrading pro-apoptotic BH3-only proteins in Chlamydia trachomatis-infected cells.

Authors:  Mustak Pirbhai; Feng Dong; Youmin Zhong; Kelvin Z Pan; Guangming Zhong
Journal:  J Biol Chem       Date:  2006-08-28       Impact factor: 5.157

3.  Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.

Authors:  Ashlesh K Murthy; James P Chambers; Patricia A Meier; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

Review 4.  Adjuvant properties of CpG oligonucleotides in primates.

Authors:  Daniela Verthelyi
Journal:  Methods Mol Med       Date:  2006

5.  The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells.

Authors:  Cathi Murphey; Ashlesh K Murthy; Patricia A Meier; M Neal Guentzel; Guangming Zhong; Bernard P Arulanandam
Journal:  Cell Immunol       Date:  2006-11-20       Impact factor: 4.868

6.  Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.

Authors:  W S Gallichan; R N Woolstencroft; T Guarasci; M J McCluskie; H L Davis; K L Rosenthal
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

7.  Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells.

Authors:  S G Morrison; R P Morrison
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells.

Authors:  S G Morrison; H Su; H D Caldwell; R P Morrison
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 9.  The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.

Authors:  G J Weiner
Journal:  J Leukoc Biol       Date:  2000-10       Impact factor: 4.962

10.  Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors.

Authors:  G Zhong; P Fan; H Ji; F Dong; Y Huang
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307
View more
  32 in total

1.  Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.

Authors:  Weidang Li; Ashlesh K Murthy; M Neal Guentzel; James P Chambers; Thomas G Forsthuber; J Seshu; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

Review 2.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

3.  TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.

Authors:  Brooke E Hjelm; Jacquelyn Kilbourne; Melissa M Herbst-Kralovetz
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

4.  Induction of protective immunity against Chlamydia muridarum intravaginal infection with the chlamydial immunodominant antigen macrophage infectivity potentiator.

Authors:  Chunxue Lu; Bo Peng; Zhihong Li; Lei Lei; Zhongyu Li; Lili Chen; Qingzhi He; Guangming Zhong; Yimou Wu
Journal:  Microbes Infect       Date:  2013-02-14       Impact factor: 2.700

5.  Frequency of Chlamydia trachomatis-specific T cell interferon-γ and interleukin-17 responses in CD4-enriched peripheral blood mononuclear cells of sexually active adolescent females.

Authors:  Romina Barral; Ruchi Desai; Xiaojing Zheng; Lauren C Frazer; Gina S Sucato; Catherine L Haggerty; Catherine M O'Connell; Matthew A Zurenski; Toni Darville
Journal:  J Reprod Immunol       Date:  2014-02-01       Impact factor: 4.054

6.  A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.

Authors:  Weidang Li; Ashlesh K Murthy; Gopala Krishna Lanka; Senthilnath L Chetty; Jieh-Juen Yu; James P Chambers; Guangming Zhong; Thomas G Forsthuber; M Neal Guentzel; Bernard P Arulanandam
Journal:  Vaccine       Date:  2013-10-01       Impact factor: 3.641

7.  Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice.

Authors:  Jieh-Juen Yu; Tatareddy Goluguri; M Neal Guentzel; James P Chambers; Ashlesh K Murthy; Karl E Klose; Thomas G Forsthuber; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-12-16

8.  Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.

Authors:  Bharat K R Chaganty; Ashlesh K Murthy; Shankar J Evani; Weidang Li; M Neal Guentzel; James P Chambers; Guangming Zhong; Bernard P Arulanandam
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

9.  A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge.

Authors:  Ashlesh K Murthy; Bharat K R Chaganty; Weidang Li; M Neal Guentzel; James P Chambers; J Seshu; Guangming Zhong; Bernard P Arulanandam
Journal:  FEMS Immunol Med Microbiol       Date:  2009-03

10.  Identifying catalytic residues in CPAF, a Chlamydia-secreted protease.

Authors:  Ding Chen; Jijie Chai; P John Hart; Guangming Zhong
Journal:  Arch Biochem Biophys       Date:  2009-05-01       Impact factor: 4.013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.